Protagenic Therapeutics, Inc.

PTIX: 10-Q · periodic report

Protagenic Therapeutics filed its 10-Q for the quarter ended June 30, 2026, reporting a net loss of $963,616 ($0.53 per share) versus a $5,057,523 loss ($1.37 per share) a year earlier, with no revenue as a development-stage biopharmaceutical company. Comparability is limited because the May 2025 reverse merger with Phytanix Bio was unwound on February 17, 2026 following a Delaware Chancery litigation settlement. The company held just $565,985 in cash at June 30, 2026, down from $1,509,178 at March 31, and stated its resources will fund operations only until approximately the end of Q3 2026 with no committed sources of additional capital, making near-term financing an existential issue for the micro-cap. Management disclosed material weaknesses in internal control over financial reporting, citing inadequate segregation of duties and heavy reliance on the Executive Chairman, and confirmed its common stock was delisted from Nasdaq effective January 5, 2026 and now trades on OTCQB as PTIX. On the pipeline, the company is refiling its IND for lead candidate PT00114, expects to begin the multiple-dose portion of a Phase Ib study in Q4 2026, and anticipates Phase IIa initiation in Q2 2027, while not expecting any product revenue before 2029.

SEC 10-Q•2mo ago

PTIX: NT 10-Q · late filing

Protagenic Therapeutics filed an NT 10-Q notifying the SEC that it cannot file its Quarterly Report on Form 10-Q for the period ended June 30, 2026 by the prescribed due date without unreasonable effort or expense. Critically, the company stated it does not expect to file the Form 10-Q within the five-day extension period provided by Rule 12b-25, meaning the reporting delay will extend beyond the standard grace window. No specific reason was given beyond that the company is working to complete remaining items. The notification was signed by Garo H. Armen, PhD, who serves as both Principal Executive Officer and Principal Financial Officer. The company indicated all prior periodic reports over the preceding twelve months were filed and no significant change in results of operations versus the year-ago period is anticipated. For a small-cap biotech, missing the quarterly deadline and already ruling out a timely catch-up filing raises questions about internal controls and accounting readiness, and warrants monitoring for potential restatements, Nasdaq compliance issues, or further disclosure problems.

SEC NT 10-Q•2mo ago

PTIX: 10-K · periodic report

Protagenic Therapeutics filed its 10-K for the fiscal year ended March 31, 2026 with explicit going-concern language: based on cash resources as of March 31, 2026, the company has sufficient funds only until the end of the third quarter of 2026 — weeks after the filing date. The company reported net income of $1,367,977 for fiscal 2026 versus a net loss of $3,591,858 the prior year, but the positive figure stems from accounting for a reverse merger with Phytanix Bio that was entered into and then unwound during the year. Protagenic has no product revenue and an accumulated deficit of $4,029,629. On the pipeline, the multiple-dose portion of the Phase I trial of lead compound PT00114 (synthetic TCAP-1) was completed in December 2025, with a Phase 2 study planned for late 2026 and an IND resubmission anticipated later in 2026. The clinical program is led by Dr. Maurizio Fava of Massachusetts General Hospital. Protagenic was delisted from Nasdaq and now trades on OTCQB under PTIX as a penny stock, with only 1,810,208 shares outstanding as of August 14, 2026 — sharply limiting liquidity, analyst coverage, and access to capital while an urgent financing need looms.

SEC 10-K•2mo ago

PTIX: NT 10-K · late filing

Protagenic Therapeutics, Inc. notified the SEC that it will be late in filing its Annual Report on Form 10-K for the period ended March 31, 2026. The company expects to submit the report within the 15-day extension period granted under Rule 12b-25. The delay is attributed to the need for additional time to complete the audit of consolidated financial statements and related disclosures. Management and the company's independent auditors require extra time to evaluate complex accounting guidance and financial reporting considerations related to a business combination transaction completed during the fiscal year. The company indicated that it does not anticipate a significant change in results of operations compared to the prior fiscal year. Garo H. Armen, PhD, the Principal Executive Officer and Principal Financial Officer, signed the notification.

SEC NT 10-K•3mo ago